Interferon antibodies may negate the antiviral effects of recombinant α‐interferon treatment in patients with chronic hepatitis B virus infection

In a randomized controlled trial of recombinant α‐2a interferon for chronic hepatitis B, interferon antibodies developed in 21 (39%) of 54 Chinese adults who received IFN. No correlation was observed between sex, age, pretreatment serum ALT level or liver histological findings and the development of interferon antibodies. Antibodies were significantly more likely to develop in patients who received lower doses (2.5 or 5 MU/m2) of α‐2a interferon than in those who received a higher dose (10 MU/m2): 53% vs. 11% (p = 0.006).

[1]  A. Lok,et al.  Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. , 1990, Journal of hepatology.

[2]  V. Carreño,et al.  Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. , 1989, Journal of hepatology.

[3]  J. Hoofnagle,et al.  Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B , 1988 .

[4]  A. Lok,et al.  A longitudinal follow‐up of asymptomatic hepatitis B surface antigen‐positive chinese children , 1988, Hepatology.

[5]  A. Lok,et al.  LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1988, The Lancet.

[6]  Figlin Ra,et al.  Anti-interferon antibodies: a perspective. , 1988 .

[7]  D. Longo,et al.  Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. , 1988, The New England journal of medicine.

[8]  Ching-lung Lai,et al.  PLACEBO-CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN , 1987, The Lancet.

[9]  H. Deicher,et al.  CLINICAL SIGNIFICANCE OF ANTI-IFN-α ANTIBODY TITRES DURING INTERFERON THERAPY , 1987, The Lancet.

[10]  R. Hoover,et al.  SERUM CHOLESTEROL AND CANCER IN THE NHANES I EPIDEMIOLOGIC FOLLOWUP STUDY , 1987, The Lancet.

[11]  Heather M. Smith,et al.  Loss of HBsAg with interferon‐α therapy in chronic hepatitis D virus infection , 1993, Journal of medical virology.

[12]  J. Gutterman,et al.  Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa‐2a by intramuscular injection , 1987, Cancer.

[13]  H. Roché,et al.  Management of cancer patients receiving interferon alfa‐2a , 1987, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[14]  M. Rainisio,et al.  The detection of antibodies to recombinant interferon alfa-2a in human serum. , 1987, Journal of biological standardization.

[15]  P. Karayiannis,et al.  Lymphoblastoid interferon therapy of chronic HBV infection. A comparison of 12 vs. 24 weeks of thrice weekly treatment. , 1987, Journal of hepatology.

[16]  J. Hoofnagle,et al.  Effect of interferon-alpha on immunoglobulin synthesis by human B cells. , 1986, Journal of immunology.

[17]  R. Spiegel,et al.  Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). , 1986, The American journal of medicine.

[18]  Y. Kawade.  [74] Quantitation of neutralization of interferon by antibody , 1986 .

[19]  J. Quesada,et al.  Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Thomas,et al.  A randomized study of the effects of adenine arabinoside 5′‐monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication , 1985, Hepatology.

[21]  A. Dibisceglie,et al.  Recombinant leukocyte interferon treatment of chronic hepatitis B , 1985, Hepatology.

[22]  J. Quesada,et al.  ANTIBODIES TO HUMAN LEUCOCYTE INTERFERONS IN CANCER PATIENTS , 1983, The Lancet.

[23]  T. Merigan,et al.  Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. , 1982, Annals of internal medicine.

[24]  I. Cobden,et al.  初期食道静脈りゅう治療におけるテルイプレシン(グリプレシン)とバソプレシンの比較試験 , 1982 .

[25]  T. Merigan,et al.  Interferon acts directly on human B lymphocytes to modulate immunoglobulin synthesis. , 1981, Journal of immunology.

[26]  T. Merigan,et al.  Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. , 1981, The Journal of infectious diseases.

[27]  D. Niethammer,et al.  Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon , 1981, Nature.

[28]  D. Addy.  BREAST IS BEST , 1976, The Lancet.

[29]  I. Gresser,et al.  Effects of interferon on antibody synthesis in vitro. , 1974, Journal of immunology.